BioStock: Biosergen attacks invisible threat of fungal infections

How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they hope will become market leading. Newly appointed CEO Tine Kold Olesen visited the BioStock Studio to discuss the invisible threat of fungi and the company’s partnership for the Indian market. In addition, CFO Niels Laursen talked about the ongoing rights issue of SEK 40.5 million and what it will finance.

Watch the full interview at biostock.se:

https://www.biostock.se/en/2024/03/biosergen-attacks-invisible-threat-of-fungal-infections

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se